Back

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Non-statin Treatment of Dyslipidemia Drug therapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study
Ms J. Pavlovic (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.
Doctor L. Lobo (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
REDUCE-IT: accumulation of data across prespecified interim analyses to final results
Professor B. Olshansky (Iowa City, US)
Abstract Slides Video
Presentation thumbnail
Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.
Professor J. Ferrieres (Toulouse, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Non-statin Treatment of Dyslipidemia

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources